# Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

> **NCT04856189** · PHASE1,PHASE2 · TERMINATED · sponsor: **Mamta Parikh** · enrollment: 4 (actual)

## Conditions studied

- Advanced Urothelial Carcinoma
- Locally Advanced Urothelial Carcinoma
- Metastatic Urothelial Carcinoma
- Refractory Urothelial Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT04856189
- **Lead sponsor:** Mamta Parikh
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-08
- **Primary completion:** 2024-01-04
- **Final completion:** 2024-02-13
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Poor accrual.
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04856189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04856189, "Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04856189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*